Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT06011798 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema
Retinal Disease
Macular Edema
Diabetes Mellitus
Diabetic Retinopathy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Edema

Interventions

DRUG: Aflibercept
DRUG: foselutoclax

Sponsor

Unity Biotechnology, Inc.